DRUG — BRIGHT MINDS BIOSCIENCES INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1827401 ·
Last close
$20.51
Market Cap
$201.25M
52W High
$123.75
52W Low
$17.40
ADV30
256,149
Next earnings
2026-12-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -11,434,277 | -2,398,255 | 310,336,533 | 307,828,515 | 2,543,873 |
| Mar 2026 | 0 | — | -15,319,423 | -10,459,627 | 312,365,111 | 309,691,863 | 3,832,687 |
| Dec 2025 | 0 | — | -6,904,082 | -7,565,318 | 90,879,853 | 89,047,867 | 1,599,304 |
| Sep 2025 | 0 | — | -5,664,542 | -4,085,603 | 84,421,539 | 82,908,589 | 2,376,616 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,361,063
Investing CF
—
Financing CF
$275,258,879
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.04
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-67,001,517
Inventory
—
Receivables
$1,101,944
ST Investments
—
EBIT TTM
$-39,322,324
Pretax Income TTM
$-24,508,803
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -13,937,584 | -12,229,348 | 84,421,539 | 2,376,616 | 82,044,923 | -8,691,619 |
| Sep 2024 | 0 | -2,822,767 | -2,801,946 | 6,104,602 | 568,259 | 5,536,343 | -1,850,186 |
| Sep 2023 | 0 | -7,386,414 | -7,372,225 | 6,879,072 | 280,856 | 6,598,216 | -7,024,265 |
| Sep 2022 | 0 | -14,975,092 | -14,964,941 | 12,086,984 | 1,544,472 | 10,542,512 | -13,587,116 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.89
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $20.76 · call volume: 32 · put volume: 21Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VOGX | Vogenx, Inc. | $200.25M | $13.48 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $205.29M | $1.90 | — |
| SIGA | SIGA TECHNOLOGIES INC | $196.16M | $2.73 | — |
| TRDA | Entrada Therapeutics, Inc. | $194.19M | $4.96 | — |
| ACIU | AC Immune SA | $209.79M | $2.11 | — |
News headlines (Yahoo Finance, 1h cache)
FDA puts partial hold on Bright Minds’ Phase II seizure study
2026-11-03 12:41 · Yahoo
Bright Minds Biosciences Faces Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Study
2026-11-02 15:51 · Yahoo
Bright Minds stock plunges as FDA halts epilepsy trial
2026-11-02 15:02 · Yahoo
Bright Minds Biosciences' BMB-101 Phase 2 Trial Placed on FDA Partial Hold
2026-11-02 12:58 · Yahoo
3 Canadian Biotech Stocks With Up To 39% Net Margins
2026-10-22 16:14 · Yahoo
Bright Minds Biosciences And 2 More Canadian Biotech Stocks
2026-10-08 09:09 · Yahoo
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
2026-09-30 21:30 · Yahoo
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
2026-08-27 16:00 · Yahoo
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
2026-08-26 13:55 · Yahoo
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
2026-07-23 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.